BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION – Trademark Portfolio
Entity Type: 03
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MICROPEL. The owner is based in PLAINVIEW, NY.
100 FAIRCHILD AVENUE
PLAINVIEW, NY 11803
Showing of trademarks Trademarks
Trademark Classifications
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION have?
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 cancelled.
What trademark classes does BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION file in?
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION's most well-known trademarks?
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION's registered trademark portfolio includes well-known marks such as MICROPEL. These are among 1 currently registered trademark in the portfolio.
What is BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION's trademark registration success rate?
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORPORATION has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.